Literature DB >> 33763348

Remodeling of Stromal Cells and Immune Landscape in Microenvironment During Tumor Progression.

Leena Arora1, Durba Pal1.   

Abstract

The molecular understanding of carcinogenesis and tumor progression rests in intra and inter-tumoral heterogeneity. Solid tumors confined with vast diversity of genetic abnormalities, epigenetic modifications, and environmental cues that differ at each stage from tumor initiation, progression, and metastasis. Complexity within tumors studied by conventional molecular techniques fails to identify different subclasses in stromal and immune cells in individuals and that affects immunotherapies. Here we focus on diversity of stromal cell population and immune inhabitants, whose subtypes create the complexity of tumor microenvironment (TME), leading primary tumors towards advanced-stage cancers. Recent advances in single-cell sequencing (epitope profiling) approach circumscribes phenotypic markers, molecular pathways, and evolutionary trajectories of an individual cell. We discussed the current knowledge of stromal and immune cell subclasses at different stages of cancer development with the regulatory role of non-coding RNAs. Finally, we reported the current therapeutic options in immunotherapies, advances in therapies targeting heterogeneity, and possible outcomes.
Copyright © 2021 Arora and Pal.

Entities:  

Keywords:  immune cell; non coding RNAs; stromal cell; tumor microenvironment; tumor progression

Year:  2021        PMID: 33763348      PMCID: PMC7982455          DOI: 10.3389/fonc.2021.596798

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  8 in total

1.  Prognostic and Immunological Value of GNB4 in Gastric Cancer by Analyzing TCGA Database.

Authors:  Binghui Liu; Lingbin Chen; He Huang; Huifeng Huang; Hui Jin; Chenglin Fu
Journal:  Dis Markers       Date:  2022-06-16       Impact factor: 3.464

Review 2.  Interplay between Solid Tumors and Tumor Microenvironment.

Authors:  Seung-Jin Kim; Dipendra Khadka; Jae Ho Seo
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

3.  Overexpression of prothymosin-α in glioma is associated with tumor aggressiveness and poor prognosis.

Authors:  Anurag Kumar; Vikas Kumar; Mohit Arora; Manish Kumar; Prajwal Ammalli; Bhaskar Thakur; Jitender Prasad; Sarita Kumari; Mehar Chand Sharma; Shashank Sharad Kale; Shyam S Chauhan
Journal:  Biosci Rep       Date:  2022-04-29       Impact factor: 3.976

Review 4.  Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment.

Authors:  Nagaja Capitani; Laura Patrussi; Cosima T Baldari
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

5.  DDR2 Expression in Cancer-Associated Fibroblasts Promotes Ovarian Cancer Tumor Invasion and Metastasis through Periostin-ITGB1.

Authors:  Favour A Akinjiyan; Ritu M Dave; Emily Alpert; Gregory D Longmore; Katherine C Fuh
Journal:  Cancers (Basel)       Date:  2022-07-18       Impact factor: 6.575

6.  [99mTc]Tc-iFAP/SPECT Tumor Stroma Imaging: Acquisition and Analysis of Clinical Images in Six Different Cancer Entities.

Authors:  Paola Vallejo-Armenta; Guillermina Ferro-Flores; Clara Santos-Cuevas; Francisco Osvaldo García-Pérez; Pamela Casanova-Triviño; Bayron Sandoval-Bonilla; Blanca Ocampo-García; Erika Azorín-Vega; Myrna Luna-Gutiérrez
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-09

7.  Development of a Multicellular 3D Tumor Model to Study Cellular Heterogeneity and Plasticity in NSCLC Tumor Microenvironment.

Authors:  Leena Arora; Moyna Kalia; Suman Dasgupta; Navneet Singh; Anita K Verma; Durba Pal
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

Review 8.  Altered BMP2/4 Signaling in Stem Cells and Their Niche: Different Cancers but Similar Mechanisms, the Example of Myeloid Leukemia and Breast Cancer.

Authors:  Boris Guyot; Sylvain Lefort; Thibault Voeltzel; Eve-Isabelle Pécheur; Véronique Maguer-Satta
Journal:  Front Cell Dev Biol       Date:  2022-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.